Boeing Co vs Cytokinetics Inc — how do they compare? Boeing Co trades at $233.4 (market cap $183.99B), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Boeing Co is far larger — about 17.1× Cytokinetics Inc's market cap, and Boeing Co pays a 0.03% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| BA | CYTK | |
|---|---|---|
Market Cap | $183.99B | $10.78B |
Volume | 7,591,579 | — |
Sector | Industrials | Technology |
52-Week High | $252.15 | $87.26 |
52-Week Low | $179.12 | $34.31 |
Enterprise Value | $209.87B | $10.88B |
Dividend Yield | 0.03% | — |
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $234.42, up 0.96% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported revenue of $89.46 billion in 2025, turning a net profit of $2.24 billion after years of losses, though margins remain thin. Recent news highlights a strategic deal with Archer Aviation, transferring three subsidiaries for a 19.75% stake, potentially enhancing Boeing's position in autonomous flight technology.
The outlook is cautiously optimistic, with a consensus price target of $284 offering ~21% upside, but risks include high debt, regulatory scrutiny from FAA inspections, and volatile cash flows. Investors should weigh the recovery in commercial aerospace against execution challenges and macroeconomic headwinds.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →